Capsida Biotherapeutics

Peter Anastasiou, CEO 

Oct. 13 | 11:15am | Oxford Biomedica Ballroom 

Thousand Oaks, CA 

(Private) 

In-person Presentation   

Capsida Biotherapeutics is the only fully integrated gene therapy platform company that through IV delivery of a single engineered capsid can target single or multiple organs simultaneously, while limiting exposure to non-targeted organs. Capsida’s approach unlocks the potential to treat both rare and common genetic and sporadic diseases across all ages. Its initial pipeline consists of multiple neurologic disease programs. The company has strategic collaborations with AbbVie and CRISPR, which provide independent validation of Capsida’s technology and capabilities. Capsida is a multi-functional and fully integrated biotechnology company with proprietary adeno-associated virus (AAV) engineering, multi-modality cargo development and optimization, translational biology, process development and state-of-the-art manufacturing, and broad clinical development expertise. Capsida’s biologically driven, high-throughput AAV engineering and cargo optimization platform originated from groundbreaking research in the laboratory of Viviana Gradinaru, Ph.D., a neuroscience professor at the California Institute of Technology. 

www.capsida.com 



By using this website you agree to accept our Privacy Policy and Terms & Conditions